George Barker

Dec 1, 2024 | renalinterventions.net | George Barker

A new research paper that was recently published in The Lancet Healthy Longevity alongside an accompanying comment article suggest that post-operative diet and exercise guidance can be beneficial for health-related quality-of-life (HRQoL) in patients that have received a kidney transplant, but that maintaining these improvements can prove to be challenging for some patients.

Nov 20, 2024 | renalinterventions.net | George Barker

SoniVie Ltd. announced today the appointment of Raymond W Cohen to serve as its chairman of the board of directors. Cohen has served as the chief executive officer (CEO) and member of the board of directors of Axonics, a global medical technology company he co-founded in 2013 and took public 31 October 2018. Axonics ranked number 1 on the 2021 Deloitte Technology Fast 500 and the 2022 Financial Times ranking of the fastest growing companies in the Americas.

Nov 18, 2024 | renalinterventions.net | George Barker

Solaris Endovascular, Inc. has recently announced its formation to develop solutions for dialysis access and peripheral artery disease (PAD). Solaris Endovascular develops evidence-based technologies, intended to treat and extend the patency of dialysis access fistulae, grafts, and peripheral arteries to allow patients to lead healthier lives with fewer interventions.

Nov 14, 2024 | interventionalnews.com | George Barker

Healionics Corporation has today announced that its STARgraft arteriovenous graft—which it states is designed to provide a safer and more reliable means of bloodstream access for kidney failure patients needing dialysis—has been granted Breakthrough Device designation by the US Food and Drug Administration (FDA).

Nov 13, 2024 | renalinterventions.net | George Barker

Xeltis has today announced that the Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA) has granted aXess Breakthrough Device Designation status. aXess is Xeltis’ vascular access conduit, which enables the creation of a new, permanent, living vessel for haemodialysis vascular access.